Wound of the Oral Cavity

DrugDrug NameDrug Description
DB10771Bovine type I collagenBovine collagen alpha-1 is a naturally occurring extracellular matrix protein which is found in tendons and other connective tissues. It plays a vital role in cell growth, differentiation, attachment, and migration [L2481]. Often combined with other ingredients, such as fibroblasts and keratinocytes, it allows for accelerated and effective wound healing [L2427], [L2450]. Excellagen, a topical gel of bovine type I collagen, is used in the management of wounds including: partial and full- thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds [L2500]. Bovine type I collagen is also used as a health supplement for bones and joints [A32698]. Interestingly, bovine type I collagen has been studied as a possible endovascular stent material, and has demonstrated promising results in rabbits [A32696].
DB10770Foreskin fibroblast (neonatal)Foreskin fibroblast-like stromal cells (FDSCs) are progenitors isolated from human tissue that can differentiate into various cell types [A32660]. Also known as Dermagraft, this device is a cryopreserved human fibroblast-derived dermal substitute. Composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold, it effectively supports wound healing [L2418]. Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. The device is available for commercial distribution in Australia, Canada, Finland, France, Hong Kong, Ireland, The Netherlands, New Zealand, Singapore, and The United Kingdom [L2418]. The impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation. If wound closure is achieved, it is likely to delay the need for surgical intervention and provide other benefits such as improvements in productivity, mental outlook, social interactions, and time at work, in addition to decreased mortality [L2438]. Interestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells [A32655]. Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427].
DB10772Foreskin keratinocyte (neonatal)Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers. The barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes. The keratinocytes form a stratified epithelium, with growing basal cells at the innermost layer and the keratinized, and mostly impermeable outer stratum corneum layer on the surface [L2452]. Foreskin keratinocytes are a form of skin cells that are cultured as a skin cell replacement for wounds, to accelerate wound closure and healing [L2434], [L2460]. The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. In 1981, O’Conner and his group utilized cultured autologous epithelium to coat burn defects for the first time. To construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. When an epidermal layer was added, this approach became known as "skin equivalent", "composite culture" or "organotypical culture" [L2453]. Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications. Keratinocytes are derived from neonatal foreskins and used to create a drug called _Apligraf_, a mixture of [DB10770] and keratinocytes. A gel made of bovine collagen is used as the matrix for cell growth and differentiation. Apligraf has been useful in the treatment of venous leg ulcers and diabetic foot ulcers, by increasing rates of wound healing and decreasing the time required for closure of wounds [L2452]. Orcel, another skin substitute, is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix. It is used for grafting onto partial-thickness wounds, where it offers a favorable matrix for host cell migration [L2452].
DrugDrug NameTargetType
DB10770Foreskin fibroblast (neonatal)Interleukin-6target
DB10770Foreskin fibroblast (neonatal)Vascular endothelial growth factor receptor 1target
DB10770Foreskin fibroblast (neonatal)Interleukin-1 receptor type 1target
DB10770Foreskin fibroblast (neonatal)TGF-beta receptor type-2target
DB10770Foreskin fibroblast (neonatal)Fibroblast growth factor 1target
DB10770Foreskin fibroblast (neonatal)Interferon gammatarget
DB10770Foreskin fibroblast (neonatal)Fibroblast growth factor receptor 2target
DB10770Foreskin fibroblast (neonatal)Granulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB10770Foreskin fibroblast (neonatal)Platelet-derived growth factor receptor betatarget
DB10770Foreskin fibroblast (neonatal)Transforming growth factor beta-1target
DB10770Foreskin fibroblast (neonatal)Tumor necrosis factortarget
DB10772Foreskin keratinocyte (neonatal)Fibroblast growth factor 1target
DB10772Foreskin keratinocyte (neonatal)Epidermal growth factor receptortarget
DB10772Foreskin keratinocyte (neonatal)Granulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB10772Foreskin keratinocyte (neonatal)Interleukin-1 betatarget
DB10772Foreskin keratinocyte (neonatal)Interleukin-6target
DB10772Foreskin keratinocyte (neonatal)Interferon gammatarget
DB10772Foreskin keratinocyte (neonatal)Fibroblast growth factor receptor 2target
DB10772Foreskin keratinocyte (neonatal)Platelet-derived growth factor receptor alphatarget
DB10772Foreskin keratinocyte (neonatal)TGF-beta receptor type-2target
DB10772Foreskin keratinocyte (neonatal)Transforming growth factor beta-1target
DB10772Foreskin keratinocyte (neonatal)Tumor necrosis factortarget
DB10772Foreskin keratinocyte (neonatal)Vascular endothelial growth factor Atarget
DrugDrug NamePhaseStatusCount